Group 1 - The core point of the article is the inclusion of Innovent Biologics in the Hang Seng ESG Enhanced Index as part of the quarterly index review by Hang Seng Indexes Company [1] Group 2 - The announcement was made on November 21, indicating a significant update in the ESG index landscape [1] - The review also included the Hang Seng ESG Enhanced Select Index and the Hang Seng China Enterprises ESG Enhanced Index, highlighting a broader focus on ESG criteria [1]

Group 1 - Hang Seng Index will include Innovent Biologics (01801), increasing the number of constituent stocks from 88 to 89 [1][4] - Hang Seng China Enterprises Index will include China Hongqiao (01378), Innovent Biologics, and Yum China (09987), while New Energy (02688) and New Oriental-S (09901) will be removed, maintaining a total of 50 constituent stocks [3][5] - Hang Seng Technology Index will include Leapmotor (09863), while ASMPT (00522) will be removed, keeping the number of constituent stocks at 30 [7][9] Group 2 - Hang Seng Composite Index will include FWD Group (01828), Hesai Technology-W (02525), Aux Group (02580), Geekplus Technology-W (02590), Yino Pharma (02591), and Chery Automobile (09973), increasing the number of constituent stocks from 503 to 509 [10][11][12]

Group 1: Hang Seng Index - Xinda Biopharmaceutical (01801) will be included in the Hang Seng Index constituent stocks, increasing the number of constituents from 88 to 89 [1][2]. Group 2: Hang Seng China Enterprises Index - China Hongqiao (01378), Xinda Biopharmaceutical (01801), and Yum China (09987) will be added to the Hang Seng China Enterprises Index, while New Energy (02688) and New Oriental Education (09901) will be removed, maintaining a total of 50 constituents [4][5]. Group 3: Hang Seng Technology Index - Leapmotor (09863) will be included in the Hang Seng Technology Index, while ASMPT (00522) will be removed, keeping the number of constituents at 30 [7][8]. Group 4: Hang Seng Composite Index - FWD Group (01828), Hesai Technology (02525), Aux Group (02580), DeepGlint (02590), Yino Pharma (02591), and Chery Automobile (09973) will be added to the Hang Seng Composite Index, increasing the number of constituents from 503 to 509 [10][11].

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

Group 1 - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] - Innovent Biologics announced that its drug IBI362 has achieved primary and all key secondary endpoints in a Phase III clinical trial for obesity, with plans to submit a new drug application for weight control [1] - The drug IBI362 is a dual receptor agonist for glucagon and GLP-1, and is the first of its kind approved globally for obesity and type 2 diabetes management [1] Group 2 - Junshi Biosciences' PD-1 inhibitor, H drug, has been officially included in the breakthrough therapy list by the NMPA for use in perioperative treatment of gastric cancer, marking a significant recognition of its clinical value [2] - This breakthrough designation is expected to accelerate the review and approval process for H drug, filling a gap in immune therapy for gastric cancer [2] - The approval of PB-119 by the NMPA highlights the competitive advantage of the drug based on solid clinical data and innovative PEGylation technology, which balances efficacy and reduces side effects [1][3] Group 3 - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs [3] - The National Healthcare Security Administration is encouraging the high-quality development of innovative drugs, indicating a warming trend in payment policies for innovative drugs [3] - Domestic pharmaceutical companies are actively transitioning towards innovation, supported by ongoing reforms in drug approval processes [3] Group 4 - Relevant Hong Kong stocks in the innovative drug sector include Heng Rui Medicine, Kelun-Botai Biopharmaceutical, and others, indicating a growing interest in the market [4]

Core Insights - The article highlights the successful completion of the GLORY-2 Phase III clinical trial for the world's first GCG/GLP-1 dual receptor agonist, Masitide, developed by Innovent Biologics, targeting severe obesity in China [1][2][3] - The trial demonstrated significant weight loss and improvements in various metabolic parameters among participants with a BMI ≥ 30 kg/m², indicating a potential new treatment option for a population lacking effective pharmacological interventions [1][2] Group 1: Clinical Trial Results - The GLORY-2 study included 462 participants with simple obesity and obesity combined with diabetes, randomized in a 2:1 ratio to receive either Masitide 9mg or a placebo for 60 weeks [2] - Results showed that the Masitide 9mg group achieved significant weight loss compared to the placebo group, along with reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels [2] Group 2: Market Potential and Regulatory Plans - Innovent Biologics plans to submit a marketing application for Masitide 9mg to the National Medical Products Administration (NMPA) for adult weight control [3] - The development of Masitide 9mg specifically addresses the weight management needs of patients with a BMI greater than 30 kg/m², particularly those above 32.5 kg/m², who previously relied on surgical interventions for effective weight management [3]

消息面上，11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临 床研究(GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg 用于成人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 信达生物(01801)尾盘涨近3%，截至发稿，涨2.62%，报92港元，成交额7.47亿港元。 ...

智通财经APP获悉，信达生物(01801)尾盘涨近3%，截至发稿，涨2.62%，报92港元，成交额7.47亿港 元。 消息面上，11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临 床研究(GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg 用于成人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 ...

增持后，JPMorgan Chase & Co.最新持好仓数目为8684.107万股，持好仓比例由4.98%上升至5.06%。 | 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信建生物製藥 | | 日期(日 / 月 / 年): | 18/10/2025 - 18/11/2025 | 格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，信达生物(01801.HK)获JPMorgan Chase & Co.以每股均价84.7327港元增持好仓 143.88万股，涉资约1.22亿港元。 | Frida Barra | 大 股東/董事/最高行政人員名 作出披露的 買 入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法國 | | --- | --- | --- | --- | --- | --- | | | 版 分享 三 | | | 和人员上面落語 | 有投票樓股期(日/月/ 份權益 | | | | | | | 份自分比 年) | | CS20251114E00461 | JPMorgan Chase & ...

智通财经APP获悉，香港联交所最新资料显示，11月11日，小摩增持信达生物(01801)143.8757万股，每 股作价84.7327港元，总金额约为1.22亿港元。增持后最新持股数目约为8684.11万股，最新持股比例为 5.06%。 ...